Transcription of [ICH E2F] [EXAMPLE DSUR – PHASE III INVESTIGATIONAL …
{{id}} {{{paragraph}}}
FICTIONAL DOCUMENT FOR ILLUSTRATIVE PURPOSES ONLY Document date: 5 October 2010 [ICH E2F] [EXAMPLE DSUR PHASE III INVESTIGATIONAL DRUG] ZB3579 Development Safety Update Report #4 Period covered: 1st January 2009 31st December 2009 Zoboryn Pharmaceuticals Taylor Science Park Five Ash Down UK TN22 3AN Signed .. [Person name, Title] Date: 21st February 2010 Note: This report contains unblinded clinical trial adverse event data This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to Zoboryn and opportunity to object FICTIONAL DOCUMENT FOR ILLUSTRATIVE PURPOSES ONLY Page 2 of 38 EXECUTIVE SUMMARY This is the 4th annual DSUR for ZB3579, summarising safety data received by Zoboryn Pharmaceuticals from 1st January - 31st December 2009.
This document contains trade secrets and confidential commercial information, disclosure of ... abdominal pain, flatulence, diarrhoea and skin rash. These were usually mild in nature. Most of the events resolved despite continued therapy, although skin rash ... provides investigators with a clear understanding of the possible risks, adverse ...
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}